Biomedicines (Jun 2022)

Isoliquiritigenin Inhibits Gastric Cancer Stemness, Modulates Tumor Microenvironment, and Suppresses Tumor Growth through Glucose-Regulated Protein 78 Downregulation

  • Chien-Hsing Lee,
  • Hsin-Yi Tsai,
  • Chun-Lin Chen,
  • Jen-Lung Chen,
  • Chao-Chun Lu,
  • Yi-Ping Fang,
  • Deng-Chyang Wu,
  • Yaw-Bin Huang,
  • Ming-Wei Lin

DOI
https://doi.org/10.3390/biomedicines10061350
Journal volume & issue
Vol. 10, no. 6
p. 1350

Abstract

Read online

Chemotherapy is the treatment of choice for gastric cancer; however, the currently available therapeutic drugs for treatment have limited efficacy. Cancer stemness and the tumor microenvironment may play crucial roles in tumor growth and chemoresistance. Glucose-regulated protein 78 (GRP78) is an endoplasmic reticulum chaperone facilitating protein folding and cell homeostasis during stress and may participate in chemoresistance. Isoliquiritigenin (ISL) is a bioactive flavonoid found in licorice. In this study, we demonstrated the role of GRP78 in gastric cancer stemness and evaluated GRP78-mediated stemness inhibition, tumor microenvironment regulation, and chemosensitivity promotion by ISL. ISL not only suppressed GRP78-mediated gastric cancer stem cell–like characteristics, stemness-related protein expression, and cancer-associated fibroblast activation but also gastric tumor growth in xenograft animal studies. The findings indicated that ISL is a promising candidate for clinical use in combination chemotherapy.

Keywords